FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_															
1. Name and Address of Reporting Person* Martin Tami Tillotson				SU	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director						
(Last)	,	First) PHARMACEUTI	(Middle)	NC.		3. Date of Earliest Transaction (Month/Day/Year) 02/23/2024								below			below)	эреспу		
9715 KEY WEST AVENUE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) ROCKV	ILLE 1	MD	20850											X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)							Rule 10b5-1(c) Transaction Indication													
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - No	n-Deriv	ative	Sec	uriti	ies Ac	quire	ed, D	isp	osed c	of, o	r Ben	eficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date						Execution Date,			⊂ c₀	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				Benefic	ies ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Co	ode V		Amount		(A) or (D)	Price	Transa	Transaction(s) (Instr. 3 and 4)			(111511. 4)		
Common Stock 02/23					/2024		A	A		1,250		0 A		87,418			D			
Common Stock 02/23/				/2024		1	F		485(1)		D	\$29.0	6 80	86,933		D				
		T										sed of				Owned				
Security or E (Instr. 3) Price Deriv	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Code (Ins				6. Date Exercisal Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable		xpiration ate	Title	1	Amount or Number of Shares					
Restricted Stock Unit	(2)	02/23/2024		T	D			1,250	(:	(3)		(3)		nmon	1,250	\$ 0	3,750		D	

Explanation of Responses:

- 1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
- 2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- 3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

/s/ Timothy C. Dec, as

02/27/2024

attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.